证券代码：300026 证券简称：红日药业 公告编号：2023-059 天津红日药业股份有限公司 天津红日药业股份有限公司 关于持股 5%以上的股东所持公司部分股份 将被司法拍卖的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津红日药业股份有限公司（以下简称"公司"、"红日药业"）近日通过 持股5%以上的股东天津大通投资集团有限公司（以下简称"大通集团"）处获悉， 天津市河西区人民法院将于2023年11月1日10时至2023年11月2日10时止（延时的 除外）在天津市河西区人民法院阿里巴巴司法拍卖网络平台上进行公开拍卖活动 （网址：https://sf.taobao.com/022/12，户名:天津市河西区人民法院）进行 公开拍卖大通集团持有的30,238,138股红日药业股票。现将有关情况公告如下： 一、股东股份被拍卖基本情况 | 股东 | 是否为控股股 东或第一大股 | 本次拍卖股 | 占其所持 | 占公司总 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | ...

Financial Performance - The company's revenue for Q3 2023 was ¥1,498,954,976.27, a decrease of 5.65% compared to ¥1,588,644,754.71 in the same period last year[14] - Net profit attributable to shareholders for Q3 2023 was ¥163,308,240.53, an increase of 38.68% from ¥118,289,981.94 in the previous year[14] - The basic earnings per share for Q3 2023 was ¥0.054, up 38.46% from ¥0.039 in the same period last year[14] - Total revenue for the third quarter was 594,034,511.44, an increase from 571,274,481.71 in the previous year, representing a growth of approximately 4.3%[44] - Net profit for the quarter was 511,963,928.67, compared to 469,519,401.08 in the same period last year, reflecting an increase of about 9.0%[44] - Operating profit was reported at 542,777,146.44, slightly up from 542,007,469.41, indicating a marginal growth[44] - The company reported a total comprehensive income of 517,401,159.03, up from 489,867,721.00, which is an increase of about 5.1%[45] - Basic and diluted earnings per share were both reported at 0.17, compared to 0.16 in the previous year, reflecting a growth of 6.25%[45] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period reached ¥992,590,001.78, a significant increase of 292.67% compared to ¥252,779,423.82 in the same period last year[14] - As of September 30, 2023, cash and cash equivalents amount to ¥1,567,242,133.35, an increase from ¥1,206,227,103.83 at the beginning of the year[24] - The cash inflow from operating activities for the current period is ¥6,020,937,137.53, compared to ¥5,892,215,938.11 in the previous period[29] - The company experienced a net cash outflow from investing activities of -155,241,916.35, an improvement from -508,830,755.94 in the previous year[48] - The company reported a decrease in short-term borrowings by 71.24% to ¥66,581,000 from the beginning of the year, primarily due to the repayment of domestic letters of credit and bank loans[8] - The company reported a 360.03% decrease in net cash flow from financing activities, amounting to -¥48,060,830.00, due to reduced borrowings and increased debt repayments[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥12,378,128,152.26, reflecting a decrease of 2.22% from ¥12,630,856,694.40 at the end of the previous year[14] - The company's total liabilities were 3.50 billion yuan, down from 4.20 billion yuan in the previous year[43] - The balance of non-current liabilities due within one year decreased by 64.94% to 152.81 million yuan, primarily due to the repayment of long-term borrowings[43] - The total liabilities rose to CNY 4,197,129,661.72, with an adjustment of CNY 29,357,575.61 from the previous period[53] - The total equity attributable to shareholders decreased to CNY 8,289,662,390.98, showing a decline of CNY 615,028.10[53] Shareholder Information - The total number of common shareholders at the end of the reporting period is 117,408, with the top 10 shareholders holding a combined 51.83% of shares[22] - Chengdu Xingcheng Investment Group Co., Ltd. holds 21.14% of shares, amounting to 634,997,417 shares, while Yao Xiaoqing holds 10.24% with 307,477,728 shares[22] - The company has not experienced any significant changes in its shareholder structure, with the top shareholders remaining consistent[22] - The number of restricted shares at the end of the period is 252,006,396, with no shares released from restriction during the current period[23] Other Financial Metrics - The company reported a non-operating income of ¥43,536,229.32 for the current period, with a total of ¥69,195,799.90 year-to-date[33] - The balance of notes payable at the end of the period was 54.36 million yuan, a 52.75% increase from the beginning of the year, mainly due to an increase in bank acceptance bills issued[35] - The balance of other current assets decreased by 39.97% to ¥96,155,000, mainly due to a reduction in pending certification and deductible input tax[17] - The company reported a 412.84% increase in minority shareholders' profit to ¥2,782,100.00, attributed to increased profits from its controlling subsidiaries[21] - Other comprehensive income at the end of the period was 6.30 million yuan, a significant increase of 632.01% from the beginning of the year, mainly due to changes in foreign currency translation differences[35] Accounting Policies and Adjustments - The company has not reported any significant impact on its financial condition or operating results due to the new accounting policies implemented from January 1, 2023[32] - As of January 1, 2023, the total assets increased to CNY 12,659,664,470.13, reflecting an adjustment of CNY 28,807,775.73 compared to December 31, 2022[53] - The total non-current assets amounted to CNY 5,274,323,486.42, with an adjustment of CNY 28,807,775.73[53] - Deferred tax assets rose to CNY 140,558,422.92, an increase of CNY 28,807,775.73[53] - The company’s third-quarter report is unaudited, indicating ongoing financial assessments[54]

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2023-056 天津红日药业股份有限公司 关于持股 5%以上的股东所持公司部分股份 将被司法拍卖的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津红日药业股份有限公司（以下简称"公司"、"红日药业"）近日通过 阿里巴巴司法拍卖网络平台查询获悉，天津市第二中级人民法院将于2023年10月 8日10时至2023年10月9日10时止（延时的除外）在天津市第二中级人民法院阿里 巴巴司法拍卖网络平台上进行公开拍卖活动（网址： https://sf.taobao.com/022/08，户名:天津市第二中级人民法院）进行公开拍 卖持股5%以上的股东天津大通投资集团有限公司（以下简称"大通集团"）持有 的3,500,000股红日药业股票。现将有关情况公告如下： 一、股东股份被拍卖基本情况 具体拍品、拍卖方式、拍卖程序、权利义务、法律责任、法律风 险等详情， 请前往天津市第二中级人民法院阿里巴巴司法拍卖网络平台 （网址： https://sf.taobao.com/022/08）进 ...

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2023-055 天津红日药业股份有限公司 天津红日药业股份有限公司 关于部分募集资金专户完成销户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、非公开发行募集资金基本情况 经中国证券监督管理委员会于 2015 年 2 月 13 日下发的《关于核准天津红日 药业股份有限公司非公开发行股票的批复》（证监许可[2015]229 号）核准，同意 天津红日药业股份有限公司（以下简称"公司"）该次募集资金非公开发行人民 币普通股（A 股）33,592,644 股，每股发行价为 28.28 元，募集资金总额人民币 949,999,972.32 元，扣除承销费、保荐费及公司发生的其他发行费用人民币 30,053,749.60 元，实际募集资金净额为人民币 919,946,222.72 元。以上募集 资金已于 2015 年 3 月 12 日到账，瑞华会计师事务所（特殊普通合伙）对公司非 公开发行股票的资金到位情况进行了审验，并于 2015 年 3 月 13 日出具了瑞华验 字【2015 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京市康达律师事务所 关于天津红日药业股份有限公司 2023 年第二次临时股东大会的法律意见书 康达股会字【2023】第 0590 号 致：天津红日药业股份有限公司 北京市康达律师事务所（以下简称"本所"）接受天津红日药业股份有限公 司（以下简称"公司"）的委托，指派本所律师参加公司 2023 年第二次临时股 东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《 ...

证券代码：300026 证券简称：红日药业 公告编号：2023-053 天津红日药业股份有限公司 2023 年第二次临时股东大会决议公告 天津红日药业股份有限公司 特别提示： 1．本次股东大会无增加、变更、否决提案的情况； 2．本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开和出席情况 天津红日药业股份有限公司（以下简称"公司"）董事会于2023年08月30日 以公告方式向全体股东发出召开2023年第二次临时股东大会的通知。本次股东大 会采取现场投票和网络投票相结合的方式召开。其中，现场会议于2023年09月18 日下午14:00在天津市武清开发区创业总部基地B01号楼公司会议室召开；通过深 圳证券交易所系统进行网络投票的时间为2023年09月18日上午09:15至09:25、 09:30-11:30，下午13:00-15:00；通过深圳证券交易所互联网投票系统投票的具 体时间为2023年09月18日09:15至2023年09月18日15:00的任意时间。 出席本次会议的股东及股东代表共24人，合计持有股份1,158,854,613股， 占公司股份总数的38.5751%。其中，出席现场会议的股 ...

天津红日药业股份有限公司 天津红日药业股份有限公司（以下简称"公司"）监事会沉痛公告，公司接 到监事会主席刘培勋先生家属通知，监事会主席刘培勋先生于2023年9月5日因病 去世。 刘培勋先生在任职期间恪尽职守、勤勉尽责，认真履行了作为公司监事应尽 的职责和义务，在保障公司监事会合规决策、维护公司及股东的整体利益等方面 尽职尽责，为公司规范运作和高质量发展发挥了积极作用。公司监事会对刘培勋 先生为公司的辛勤付出和贡献深表感谢。公司董事、监事、高级管理人员及全体 员工对刘培勋先生的去世表示沉痛哀悼，并向其家属表达深切慰问。 刘培勋先生去世后，公司监事会成员低于法定最低人数，公司将按照相关法 定程序尽快完成监事补选工作并及时履行信息披露义务。 公司董事、监事、高级管理人员将继续致力于公司发展，公司的生产经营活 动不会因此受到影响。 特此公告。 天津红日药业股份有限公司 关于公司监事会主席去世的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 证券代码：300026 证券简称：红日药业 公告编号：2023-052 天津红日药业股份有限公司 监 事 会 二○二三年九 ...

Q6：请问贵公司子公司超思电子的产品单一问题如何解决？血氧 仪市场很小，也饱和啊？ 编号：2023-02 您好！在报告期内，超思电子新产品智能制氧机、脉冲便携 式制氧机完成量产并已上市，丰富了公司产品线，有助于提升公 司产品的市场竞争力，同时还有一些新品在研发。感谢您的关注！ Q7：请问中药配方颗粒是否可以在第三终端诊所销售？可以的 话，贵公司目前在这方面有哪些布局和进展？ | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 通过全景网"全景路演"（https://rs.p5w.net）参与 2023 年度 | | 人员姓名 | 天津辖区上市公司半年报业绩说明会暨投资者网上集体接待日活 | | | 动的投资者 | | 时间 | 2023 年 9 月 5 日（星期二）下午 13:30 至 16:50 | | 地点 | 全景网"全景路演"（https://rs.p5w.net） | | 上市公司接待人 | ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2023, representing a year-on-year increase of 15%[26]. - The company has reported a 30% increase in overall revenue for the first half of 2023 compared to the same period last year[7]. - The company has set a revenue guidance of 1.5 billion yuan for the next quarter, representing a 20% increase compared to the previous quarter[7]. - Future guidance indicates an expected revenue growth of 10-15% for the full year 2023[26]. - The net profit attributable to shareholders reached RMB 100 million, up 20% compared to the same period last year[26]. - The gross margin improved to 45%, up from 42% in the previous year, indicating better cost management[26]. Market Expansion and Product Development - The company is focusing on market expansion, targeting a 15% increase in market share by the end of the fiscal year[7]. - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in sales in that region[26]. - New product development is underway, with an expected launch of three innovative medical devices in Q4 2023[7]. - The company plans to launch three new products in the second half of 2023, focusing on traditional Chinese medicine[26]. - A strategic acquisition of a local pharmaceutical company is in progress, expected to be finalized by Q4 2023[26]. Research and Development - The company is investing heavily in R&D, allocating 10% of its revenue to new technology development[7]. - Research and development expenses increased by 18%, reflecting the company's commitment to innovation[26]. - The company has invested 76 million yuan in collaboration with the Shanghai Institute of Materia Medica to develop a new antiviral drug for hepatitis C, enhancing its core competitiveness[144]. - The R&D center construction project has a total committed investment of CNY 66.01 million, with an adjusted total of CNY 159.49 million, achieving an investment progress of 86.82%[166]. Environmental Management - The company has implemented an environmental monitoring plan in compliance with regulatory requirements, ensuring adherence to pollution control standards[108]. - The company reported an environmental protection investment of CNY 2.6 million and paid CNY 12,000 in environmental protection tax during the reporting period[83]. - The company has established a new plan for environmental management and protection based on its current environmental situation, which was filed in October 2022[82]. - The company’s wastewater treatment facilities are operating normally and achieving standard discharge[78]. - The company has obtained environmental protection administrative permits, with the validity period for its pollution discharge permit from December 3, 2021, to December 2, 2026[72]. Corporate Governance and Compliance - The company has not engaged in any major asset or equity acquisitions or sales during the reporting period, maintaining a conservative approach to capital management[89]. - There were no significant litigation or arbitration matters reported during the reporting period, indicating a stable legal environment for the company[88]. - The company has not experienced any significant penalties or violations during the reporting period, reflecting effective compliance measures[110]. - The company reported no overdue commitments from shareholders or related parties, demonstrating strong governance and accountability[87]. Financial Management - The company has not engaged in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[152][153][156]. - The company has confirmed a payment of CNY 15 million for a contract related to tumor immunotherapy small molecule drugs[1]. - The company has a total guarantee amount approved for subsidiaries of CNY 145.60 million, with actual guarantees amounting to CNY 27.53 million during the reporting period[173]. - The actual guarantee balance at the end of the reporting period is CNY 87.07 million, which accounts for 10.18% of the company's net assets[173]. Shareholder Information - The company’s largest shareholder, Chengdu Xingcheng Investment Group, holds 20.24% of shares, amounting to 608,080,817 shares, with a pledge of 243,820,162 shares[3]. - The total number of unrestricted shares before the change was 2,703,624,442, representing 90.00% of total shares[198]. - After the change, the number of unrestricted shares increased by 48,523,999, resulting in 2,752,148,441 unrestricted shares, which is 91.61% of total shares[198].

主管会计工作的负责人:蓝武军 会计机构负责人:孙武 1 单位:万元 天津红日药业股份有限公司 2023年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | | 占用方与上市公 | 上市公司核算 | 2023年期初占用 | 2023年1-6月占用累计发 | | 2023年1-6月占 2023年1-6月偿还 | 2023年6月期末 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占用方名称 | 司的关联关系 | 的会计科目 | 资金余额 | 生金额(不含利息) | 用资金的利息 | 累计发生金额 | 占用资金余额 | 占用形成原因 | 占用性质 | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | 非经营性往来 | | 小计 | - | - | - | | | | | | - | | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | | 非经营性往来 | | 小计 | - | - | - | | | | | | - | | ...